NEW YORK, March 25, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief Financial Officer, David Guebert, will be retiring from his position on March 31, 2022. “On behalf of the Board of Directors and Executive…


Previous articleNova Mentis Begins Enrollment in North American Autism Study
Next articleMindMed Reports Full Year 2021 Financial Results and Business Highlights